Loading
Blood tests for bowel cancer miss most precancerous polyps, so they should not replace stool tests. But for the third of people who never do any screening, a blood test may beat nothing.
Shield (Guardant) is FDA-approved with about 83% sensitivity for colorectal cancer but around 13% for advanced adenomas; the concern is substitution away from FIT and colonoscopy. Propose a randomised trial in persistent non-responders: blood test offer versus repeat FIT offer, endpoint stage I-II cancers detected per 1,000 invited.
Shares Early detection of cancer, Prevention we already have is not deployed, The hardest cancers are found late.
Shares Early detection of cancer, Prevention we already have is not deployed, The hardest cancers are found late.
Shares Shield, Early detection of cancer, The hardest cancers are found late, Liquid biopsy (ctDNA).
Shares Shield, Guardant Health, Early-onset colorectal cancer (under 50), Liquid biopsy (ctDNA).
Shares Early detection of cancer, Prevention we already have is not deployed, The hardest cancers are found late.
Shares Early detection of cancer, The hardest cancers are found late, Liquid biopsy (ctDNA).
Shares Early detection of cancer, The hardest cancers are found late, Liquid biopsy (ctDNA).
Shares Early detection of cancer, The hardest cancers are found late.